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INTRODUCTION
Placebo was conceived as an epistemological tool to control for incidental factors that could
influence investigated outcomes (1, 2). As a phenomenon, placebo has been conceptualized in
many different ways, both theoretically and practically, although a generally accepted definition
is still to be devised (3). In clinical research setting it is, however, helpful to distinguish placebo
response from placebo effect. Placebo response is considered to be the composite change observed
in individuals after administration of placebo, consisting of different aspects, such as natural course
of the disease and methodological artifacts, as well as the placebo effect itself (4, 5). Placebo
effect would therefore be the change observed in individuals after controlling for natural course
of the disorder, methodological aspects, and the effect linked to treatment-specific features (i.e.,
antidepressant verum) (1). In other words, placebo responses may or may not include placebo
effect as genuine psychobiosocial effect that is usually attributed to various features of treatment
situation and contexts (5). Recent findings consistently show a modest average effect (a mean effect
size of d = 0.30) of antidepressants above placebo in short-term treatment of adult depression
(6, 7). This could be interpreted as strong evidence of a modest effect. Whether this effect on
outcome measures, that are rather limited and subjective, is clinically meaningful remains an open
question (8). Issues of true long-term efficacy, safety and cost-effectiveness of antidepressant drugs
still loom over the horizon (8–11). Still, these recent findings pose interesting questions, since
similarly consistent findings have been published showing a large and highly variable placebo effect
in studies aiming to prove true efficacy of antidepressants (12, 13). In other words, participants in
antidepressant studies that are receiving, at least from a theoretical point, a supposedly inherently
neutral intervention (one that should be lacking known, relevant, and specific features), show
substantial and consistent improvement across different study designs and contexts.
CONTEXT
Double blind randomized placebo-controlled trials (DBRPCT) have long been considered to
be the golden standard for determining true efficacy of an intervention. As such, DBRPCTs
are based on the logic that reflects the basic premises of scientific epistemology: it allows
a certain degree of control over factors that could influence outcomes of interest, but at
the current point is not a subject of scientific inquiry (3). Randomization, blinding, and
placebo control groups allow for probabilistic balancing of these unspecific factors, and
prevent intentional or accidental influence from study participants and investigators (14).
Consequently, it is assumed that true effect of intervention could be extracted based on the
“additivity assumption”—true effect is one that is present only within the last remaining
uncontrolled therapeutic features, and therefore attributed to the intervention being investigated.
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Such a design, created for a very specific purpose, has
its shortcomings that have been widely discussed [for
more comprehensive discussion consider (14) and related
commentaries]. In order for a DBRPCT to be internally valid
(able to fulfill its explanatory purpose), a certain degree of
deviation from external validity is required, causing loss of
similarity to the targeted model—clinical practice (14, 15).
Placebo in DBRPCTs was initially conceived as a procedure that
allows blinding, removing the influences of study participants
and investigators. It seems, however, that placebo consistently
influences outcomes above and beyond its anticipated boundaries
(1, 16, 17). Although we aim to constrain “human factor,” certain
aspects of human nature evade such attempts. Human subjects,
inherently vulnerable because of the nature of their medical
condition, are systematically and consistently reacting to a
more or less specific set of internal and external cues, creating
a “genuine” placebo effect. While placebo effect may be a
valuable and legitimate object of research, one should be
careful not to overgeneralize this term, since a tendency to
erroneously characterize everything and anything as a placebo
effect can be seen [for more detailed discussion consider (18)].
In other words, as previously mentioned, genuine placebo
effect should be distinguished from methodological artifacts
that exert certain influence on outcomes, such as natural
course of the investigated condition, spontaneous variation in
symptoms, and various sources of research bias (2, 18, 19). It
seems that genuine placebo effect exercises a greater influence
in its own right than any of above mentioned factors, and
as such is neither inert nor unspecific. It is responsible for
physical changes and effects in individuals that are specific
and somewhat related to the investigated condition and/or
effects of “true” treatment (1, 2, 16, 19, 20). The placebo effect
is considered to be an adaptive process that emerges from
contextual and individual features within a treatment situation,
and as such is driven by underlying biological, psychological
and social components that are not mutually exclusive [for
further details consider: (1, 21)]. As such, the placebo effect
may contradict the additivity assumption, influencing outcomes
conjointly or even independently from the investigated
intervention (1). Therefore, an “interactive” assumption has
been proposed, acknowledging that underlying mechanisms
that yield a therapeutic response interact in a complex
manner (1, 22).
RECENT FINDINGS
Findings suggest that placebo effect in antidepressant trials
is a genuine entity, and as such may be distinguished from
methodological artifacts that are also exhibiting a substantial
influence on outcomes (23–25). While recent findings suggest
that antidepressants show therapeutic efficacy and effectiveness,
it seems that placebo effect may be one of the key driving forces
of their effect. Moreover, it has been suggested that as much as
88% of antidepressants efficacy could be attributed to the placebo
effect (8). In other words, antidepressants would in that case
have little additional specific effect beyond the placebo effect.
Furthermore, recent analyses found that a subset of 17% of
individuals with depression could exhibit “clinically significant
advances” with placebo relative to antidepressants (26). Similarly,
earlier findings suggested that 20% of individuals with depression
could have a worse disease trajectory with antidepressant than
with placebo therapy (27).
Moderators and mediators of placebo and antidepressant
effects have been thoroughly investigated and reviewed [more
thoroughly discussed in: (28, 29)]. Unbalanced studies group
randomization and effect modulation by baseline severity
have been previously singled out as most consistent and
robust findings. It may seem intuitive that baseline severity
of depression influences responses to any given intervention,
and it has long been argued that as depression is more
severe, placebo effects are less prominent, while response rates
to antidepressants remain stable (28, 30). This concept was
recently dismissed, as antidepressants or placebo intervention
seems to be equally (in)effective across the whole depression
severity spectrum (31, 32). Interestingly, recent findings even
suggest that placebo response rates seem to be similar in
persistent depressive disorder (defined as all forms of depressive
conditions that persist for at least 2 years) compared to
episodic depression (33). The probability of receiving placebo
(unbalanced group randomization) has been repeatedly and
firmly correlated with the antidepressants’ response (12, 29, 34).
This relationship has a linear gradual effect, with efficacy of
antidepressants increasing as we move from greater toward
lower probability of receiving placebo. So, antidepressant
response rates are significantly higher in comparator trials
than in DBRPCT. This finding is usually interpreted as
implicit evidence that both placebo and treatment effects
could be based on patient expectations (that could obviously
be positive and/or negative) (12). Nonetheless, it has been
shown that expectations (conceptualized as perceived treatment
assignment) significantly change during studies while retaining
their relative predictive power (35). What participants believe
may be more important than what they actually receive
as an intervention, making a false but sincerely held belief
more important that actual intervention. Some advancement
has been made in predicting antidepressant and placebo
responses and/or responsiveness in research and clinical practice.
Although certain neurobiological features, clinical and socio-
demographic characteristics of patients have been highlighted
as possible outcome predictors, low sensitivity and high intra-
and inter-individual variability remain an issue (26, 36–38).
Placebo responsiveness, and to lesser account antidepressant
responsiveness remain highly and complexly variable on
all levels.
DOES PLACEBO EFFECT HAVE AN
EFFECT ABOVE AND BEYOND THAT
OF ANTIDEPRESSANTS?
Many questions are still unanswered regarding characteristics,
mechanisms and definition of the placebo response and effect.
Line of research dealing with those issues could be referred to
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as “placebo explanatory research,” and depression and psychiatry
disorders in general could be seen as particularly fertile ground
for these inquiries (1, 2, 16, 24, 25, 29). For example, open-
label placebo administration with full disclosure, seems to yield
similar antidepressant therapeutic effects as the traditionally
administered ones (39). On the other hand, antidepressants
compared with active placebos that imitate some side-effects
showed no significant advantage (40). Thus, expectation related
placebo effects may be driven by unblinding properties of
side-effects, and further diminishing antidepressants’ signaling
potential (extricating true efficacy).
We consider “antidepressant explanatory research” as one
being primarily oriented toward proving true antidepressants
efficacy.Within this approach, it has been recently argued that the
placebo control group should be completely omitted, as diverse
variability of placebo effects seems to undermine internal validity
making studies fundamentally invalid and uninterpretable
(7, 12). Proponents of keeping the placebo control group,
propose methodological and analytical approaches that aim to
control and manage placebo effects [further details may be
found in: (1, 41, 42)]. One of the underlying assumptions
is that “placebo responders” influence outcomes blurring the
antidepressants’ signaling potential. Hence, different methods,
such as placebo run-in phase could be applied in order to
eliminate these obstacles. This approach should be considered
ethically and methodologically erroneous as there is no evidence
that such a stable trait exists. Just the opposite, it seems that
placebo responsiveness emerges from complex interrelationship
between stable and situational traits [recently elaborated in:
(19)]. Furthermore, it could be argued that reduction of
placebo responsiveness will further reduce antidepressants
responsiveness (25). Similar logic is applied within the approach
of risk modeling where “risk participants” (disproportionately
contributing to the outcome) and/or “non-responders” (not
prone to react regardless of assigned intervention) are further
dealt in identify and mitigate manner (1, 42). All of these
strategies may be considered pragmatic, as there is great
pressure to reduce ineffectual research. There are other strategies
that tackle different possible sources of error by manipulating
study context, design, conduct and analysis with primary
aim to enhance studies’ internal validity, antidepressants’
signal detection potential and yield more historically reliable
response rates (1, 2, 16, 20, 25, 28, 41–43). However,
these strategies tend to increase internal validity at the
expense of external validity, and as such seem more like
a harm reduction strategies than as true advancement of
our understanding of the complex underlying phenomena
(14, 18, 25, 44, 45). Following this line of argumentation,
solutions could include introduction of an independent study
investigator and the concept of “cold standardization”—a
virtual, computer driven standardized recruitment, admission
of interventions and assessment of study participants. Such
an approach would have potential to eliminate some features
of intrapersonal healing that has been singled out as possibly
one of the major contributors to the placebo effect, tackle
widespread issue of inadequate blinding and other sources of
investigator or study-staff related biases (14). Although such (still
hypothetical) computerized study investigator could standardize
study recruitment, administration and assessment procedures,
it would not be resistant to other sources of bias. One could
even imagine that participants’ expectations in such a setting
would change in previously unimaginable directions (either by
certain therapeutic potential of this interaction or properties of
interventions itself, such as side effect profile). Although here
being used as extreme argument on how one could possibly
further strengthen studies internal validity, such an approach
could be also used in order to distinguish specific features
underlying placebo and/or therapeutic effects (serving a more
pragmatic purpose).
Alternatively, “antidepressant pragmatic research” would steer
toward comprehending complex interactions of specific and/or
unspecific features that are contributing to a therapeutic effect.
We should not try to simply manage placebo effects, but
direct our attention to its understanding through rigorous
initial planning, assessment, reporting and sharing of all data
possibly linked to the therapeutic response as well as non-
response (1, 17, 19, 20, 43, 44). In other words disentangling
of the placebo enigma seems to carry the potential of being
the royal road to answering presumably the most important
question at hand: which elements of the intervention, and
in what proportion, are the ones relieving the suffering? In
that sense, inclusion of an additional study arm in which
the primary aim is to reach the maximum possible efficiency
through any means necessary could be labeled as “warm
standardization” (25). Again, different means could be used
for that purpose, for example harnessing and maximizing
expectations or even including additional specific interventions
(such as some form of specific psychotherapy—being previously
conceived as inherently expectation modulatory treatment) (46).
Finally, as placebo is a relational phenomenon that significantly
differs from context to context, all known moderators and
mediators of placebo effect (from its physical characteristics
to informed consent process) should be rigorously reported
(1, 2, 16, 17, 43). Factors that affect treatment outcomes
need to be evidenced, extrapolated, weighted, agglomerated,
and discussed having in mind that acquiring scientifically
grounded knowledge is an iterative, cumulative process.
Currently, novel analytical tool, such as computational methods
allow us to amplify robustness of other data rich sources,
such as electronic health records, while searching for the
structures of causality that could be more rooted in real
world estimates of certain interventions safety, efficacy and
effectiveness (14, 45, 47–49).
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